Side-by-side · Research reference

PinealonvsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft12/36 cited

BPhase 2Reviewed8/46 cited

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Pinealon

TB-500

Primary target

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Pinealon

TB-500

Standard dose

5–10 mg / day for 10 daysKhavinson 2014

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

Once daily during cycle

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

2.5 mg / day

1 mg per injection

Evidence basis

Russian clinical trials + in vitroKhavinson 2014

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Duration

10-day cycles, 1–2× per year

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

Bacteriostatic water

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

No specific time

Evening or pre-rest preferred (anecdotal)

Half-life

Hours

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

Pinealon

TB-500

Injection site reaction

Mild irritation

Mild erythema, transient pain

Long-term safety

Limited Western data

Unknown beyond Phase 2

Pregnancy / OB

Avoid

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Absolute Contraindications

Pinealon

·Pregnancy / breastfeeding

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Pinealon

·Active malignancy (theoretical via gene expression modulation)

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Pinealon

TB-500

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Injection site

SQ — abdomen preferred.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Timing

Daily during cycle, any time.

Evening or pre-sleep is most common anecdotal timing.

4. Storage

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair